HIV-1 proviral DNA loads (as determined by quantitative PCR) in patients subjected to structured treatment interruption after antiretroviral therapy failure

Journal of Clinical Microbiology

Volumn 50, Issue 6, 2012, Pages 2132-2133

  Komninakis, Shirley Vasconcelos ^a   Santos, Domingos E M ^a   Santos, Carlos ^b   Oliveros, Márcia P R ^b   Sanabani, Sabri ^b   Diaz, Ricardo S ^a,b  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; VIRUS DNA;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL PROTOCOL; DNA EXTRACTION; DRUG TREATMENT FAILURE; FEMALE; GENE AMPLIFICATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MALE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; STRUCTURED TREATMENT INTERRUPTION; VIRUS LOAD; VIRUS REPLICATION; VIRUS STRAIN;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CELLS, CULTURED; DNA, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; PROVIRUSES; REAL-TIME POLYMERASE CHAIN REACTION; TREATMENT FAILURE; VIRAL LOAD; WITHHOLDING TREATMENT;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84862104607     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.00393-12     Document Type: Article

References (10)

1. Christopherson C, et al. 2000. PCR-based assay to quantify human immunodeficiency virus type 1 DNA in peripheral blood mononuclear cells. J. Clin. Microbiol. 38:630-634. (Pubitemid 30082654)
2. Chun TW, et al. 1997. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 387:183-188.
3. Chun TW, et al. 2002. Relationship between the size of the human immunodeficiency virus type 1 (HIV-1) reservoir in peripheral blood CD4+T cells and CD4+:CD8+T cell ratios in aviremic HIV-1-infected individuals receiving long-term highly active antiretroviral therapy. J. Infect. Dis. 185:1672-1676.
4. Chun TW, et al. 2005. HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir. J. Clin. Invest. 115:3250-3255.
5. Deeks SG, et al. 2001. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N. Engl. J. Med. 344:472-480. (Pubitemid 32164898)
6. Désiré N, et al. 2001. Quantification of human immunodeficiency virus type 1 proviral load by a TaqMan real-time PCR assay. J. Clin. Microbiol. 39:1303-1310. (Pubitemid 32275425)
7. Miller V, et al. 2000. Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure. AIDS 14: 2857-2867. (Pubitemid 32042749)
8. Nottet HS, et al. 2009. HIV-1 can persist in aged memory CD4+ T lymphocytes with minimal signs of evolution after 8.3 years of effective highly active antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 50: 345-353.
9. Yerly S, et al. 2004. Proviral HIV-DNA predicts viral rebound and viral setpoint after structured treatment interruptions. AIDS 18:1951-1953. (Pubitemid 39313211)
10. Zhang H, et al. 1998. Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy. N. Engl. J. Med. 339:1803-1809. (Pubitemid 29005784)